PI4K
The term phosphatidylinositol (PtdIns) cycle was coined in the mid 50's of the last century, probably in reminiscence to the detection of major metabolic cycles detected and named shortly before. Three PI4K isoforms which we called PI4K230, PI4K92 and PI4K55 (according to the molecular weights of the corresponding proteins of 230,92 and 55 kDa) have now been cloned and sequenced. All three PI4K isoforms differ greatly in their N-terminally located regulatory domains. Both PI4Ks (230 and 55) contain structural elements responsible for association with membranes: PI4K230 a pleckstrin homology (PH) domain and PI4K55 a palmitoyl residue. Potential phosphorylation sites in PI4K230 suggest regulatory function of CAMP-dependent protein kinase (PKA), protein kinase-C, caseine kinase I1 and protein tyrosine kinases; PI4K92 has a high potential for regulation by phosphorylation; eight sites have been identified indicating participation of proline directed cyclin-dependent protein kinases, like cdc2, or cyclic monophosphate-dependent protein kinases (PKA/PKG; and ca2 + / calmodulin-dependent protein kinase (CaMKII).
References
1.Heilmeyer LM Jr,et al. IUBMB Life. 2003;55(2):59–65.
References
1.Heilmeyer LM Jr,et al. IUBMB Life. 2003;55(2):59–65.
PI3K/Akt/mTOR signaling
PI4K
-
(3S)-GSK-F1
catalog no : M36017
cas no: 1384097-27-1
(3S)-GSK-F1 is a selective small molecule inhibitor of Type III Phosphatidylinositol 4?Kinase Alpha (PI4KIIIα), pIC50=8.3. -
AZ044
catalog no : M34168
cas no: 1800017-49-5
AZ044 is a potent, selective inhibitor of type III phosphatidylinositol-4-kinase alpha-subtype (PI4KIIIalpha). -
GSK-F1
catalog no : M27172
cas no: 1402345-92-9
GSK-F1 is a novel potent PI4KA inhibitor. -
PI-273
catalog no : M16628
cas no: 925069-34-7
PI-273 (PI273) is a potent, specific, substrate-competitive small molecule inhibitor of PI4KIIα with IC50 of 0.47 uM. -
PIK-93
catalog no : M15202
cas no: 593960-11-3
PIK-93 is a potent, synthetic PI4K inhibitor with IC50 of 19 nM (PI4KIIIβ).